Aeglea BioTherapeutics Inc

NASDAQ:AGLE   3:59:59 PM EDT
7.09
-0.15 (-2.07%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)347.56M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$13 Million
Adjusted EPS-$0.19
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Aeglea BioTherapeutics Inc Stock, NASDAQ:AGLE

805 Las Cimas Parkway, Suite 100, Austin, Texas 78746
United States of America
Phone: +1.512.942.2935
Number of Employees: 90

Description

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.